The stock is moving higher as the broader market is experiencing positive momentum, with the Nasdaq up 0.62% today, contributing to the bullish sentiment.Earnings SnapshotTandem Diabetes on Thursday reported a smaller-than-expected fourth quarter adjusted loss of one cent compared to the consensus loss of eight cents.Sales increased 3% year over year to $290.4 million, beating the consensus of $277.03 million.Adjusted gross profit jumped from 51% to 58%. The company reported adjusted operating profit of $8. ...

Expro Group Holdings (NYSE:XPRO) Q4 2025 Earnings call February 19, 2026 11:00 AM ET Company ParticipantsDave Wilson - Head of Investor RelationsEddie Kim - VP of Equity ResearchMike Jardon - CEOSergio Maiworm - CFOConference Call ParticipantsAti Mody - Equity Research AnalystColby Sasso - Equity Research AnalystDerek Podhaizer - Equity Research AnalystJosh James - Equity Research AnalystOperatorLadies and gentlemen, the Expro Q4 2025 earnings presentation will begin shortly with your host, Dave Wilson. We ...

Ingersoll Rand (NYSE:IR) FY Conference Summary Company Overview - **Company**: Ingersoll Rand - **Date of Conference**: February 18, 2026 Key Industry Insights - **Demand Environment**: - Positive momentum observed in Q4 2025, with organic growth in orders across segments, particularly in North America and China, which accounts for about 10% of revenue [4][6] - Leading indicators like PMI are showing positive inflections, suggesting a potential recovery in the U.S. short-cycle industrial market [8][10] - The company is maintaining a prudent outlook for 2026, with expectations for organic growth to be modest [10][29] - **Headwinds**: - Previous headwinds from various global events (e.g., China EV build-outs, European market fluctuations post-Ukraine invasion) are no longer significant concerns as the company moves into 2026 [14][17] - The company does not foresee new comparable headwinds emerging in the near term [14][17] Financial Performance - **Recurring Revenue Growth**: - Recurring revenue exceeded $450 million in 2025, up from approximately $200 million in 2023, indicating more than a doubling of this revenue stream [24][25] - Growth in recurring revenue is broad-based across regions and product categories, with compressors in the U.S. being the largest contributor [25][27] - **Profitability**: - The recurring revenue model, particularly the Package Care segment, has gross margins between 60%-70%, contributing to overall profitability [41][46] - The company achieved a 29% EBITDA margin in ITS, with expectations for continued margin expansion despite tariff headwinds [46][61] Market Dynamics - **Tariff Impact**: - The company has experienced tariff exposure but has managed to offset these costs through pricing strategies, maintaining a dollar-neutral price-cost dynamic [54][55] - The market has responded rationally to tariff impacts, with pricing actions taken to mitigate margin dilution [54][58] - **Competitor Landscape**: - Competitors have varied responses to tariff impacts, with some implementing significant price increases while others balance pricing strategies [57][58] Strategic Focus - **Capital Allocation**: - The company plans to allocate 80%-85% of free cash flow towards M&A, with expectations for continued bolt-on acquisitions in the $1 billion range [95][99] - Share repurchase is targeted at $300-$350 million for the year, with no changes expected in the dividend policy [99][100] - **Growth Areas**: - Focus on under-penetrated markets such as Latin America, India, and Southeast Asia, with significant order growth observed in these regions [61][62] - Continued investment in innovation and recurring revenue initiatives is expected to drive future growth [61][64] Conclusion - Ingersoll Rand is positioned for a cautious yet optimistic outlook in 2026, with a focus on organic growth, recurring revenue expansion, and strategic capital allocation. The company is navigating past headwinds effectively and is set to capitalize on emerging opportunities in various global markets.

LCI Industries (NYSE:LCII) Q4 2025 Earnings call February 18, 2026 08:30 AM ET Company ParticipantsDaniel Moore - Partner and Director of ResearchJason Lippert - President and CEOKevin Condon - Vice President and Senior Equity Research AssociateLillian Etzkorn - CFOConference Call ParticipantsBrandon Roll`e - Managing Director and Senior Equity Research AnalystBret Jordan - Managing Director and Senior Equity Research AnalystJoe Altobello - Managing Director and Senior Equity Research AnalystMike Albanese - ...

Bausch + Lomb (NYSE:BLCO) Q4 2025 Earnings call February 18, 2026 08:00 AM ET Company ParticipantsAndrew Stewart - President of Global Pharmaceuticals and International ConsumerBrent Saunders - Chairman and CEODavid Roman - Managing DirectorDouglas Miehm - Managing DirectorGeorge Gadkowski - VP of Investor Relations and Business InsightsJoanne Wuensch - Managing Director, Head of U.S. Healthcare ResearchPatrick Wood - Managing DirectorSam Eldessouky - CFOYehia Hashad - EVP and Chief Medical OfficerConferenc ...

Core Viewpoint - Phibro Animal Health Corporation (NASDAQ:PAHC) is recognized as one of the seven cheap pharmaceutical stocks to consider for investment, particularly noted for its strong operational performance and positive financial outlook [1][2]. Financial Performance - For the fiscal second quarter ending December 31, 2025, Phibro reported a 21% increase in net sales to $373.9 million and a rise in net income to $27.5 million [4]. - Adjusted EBITDA increased by 41% to $68.1 million, while adjusted diluted EPS rose by 58% to $0.87 [4]. - The company has updated its fiscal 2026 net sales estimates to between $1.45 billion and $1.50 billion, with adjusted EBITDA projected between $245 million and $255 million, reflecting improved operating momentum [5]. Analyst Ratings - Morgan Stanley raised its price target for PAHC from $45 to $49, maintaining an Equal Weight rating, citing strong operational performance and effective execution in the Animal Health segment [3]. - The upgrade was influenced by significant margin expansion, a favorable fiscal 2026 forecast, and a profit beat in the second quarter [3].

Core Insights - Investors seek stocks that provide substantial gains, and identifying such opportunities requires a structured approach [1] Group 1: Sales Growth - Sales growth is essential for profit generation, enabling companies to achieve efficiencies and enhance shareholder value [2] - Nvidia serves as a prime example, with its stock price significantly increasing due to strong sales growth in its Data Center segment [2] Group 2: Margins - Margin performance indicates operational efficiency, reflecting a company's ability to generate more profit from sales [3] - Companies like Eaton have demonstrated improved profitability, leading to margin expansion and a corresponding rise in stock prices [3] Group 3: Innovation - Innovation is critical for maintaining and expanding market share, allowing companies to stay competitive [4] - Nvidia's advancements in artificial intelligence have propelled its stock and positioned it prominently in market discussions [4] Group 4: Earnings Estimates - Positive revisions in earnings estimates are crucial for stock price appreciation, with the Zacks Rank system categorizing stocks based on these estimates [5] - The Zacks Rank has effectively captured the recent upward movement in stocks like SanDisk [6] Group 5: Common Traits of Outperforming Stocks - Outperforming stocks typically exhibit characteristics such as significant sales growth, margin expansion, and favorable earnings estimate revisions [7] Conclusion - Key factors contributing to stock outperformance include robust sales growth, margin expansion, innovation, and positive earnings estimate revisions [8]

PresentationUnknown Analyst All right. Good afternoon. It's my pleasure to introduce Unilever, one of the world's most important global consumer franchises with category-leading positions across wellness, home, personal care and food and deep exposure to the world's fastest-growing end markets. Over the past year, Unilever has reached a clear inflection point under a refreshed Board of Directors, new CEO and CFO. The company is moving with urgency, simplifying its portfolio, completing the Magnum Ice Cream ...

Core Viewpoint - Espey Mfg. & Electronics Corp. has experienced a significant decline in stock price despite reporting increased net income, indicating potential market concerns despite improved profitability metrics. Financial Performance - For Q2 of fiscal 2026, Espey reported net income of $0.99 per share, an increase from $0.71 per share in the same quarter last year [1] - Net sales decreased by 10.8% to $12.1 million from $13.6 million a year earlier, yet net income rose by 47% to $2.8 million compared to $1.9 million in the prior-year quarter [2] - Gross profit increased to $4.2 million from $3.2 million, raising gross margin to 34.7% from 23.2%, attributed to product mix, labor efficiencies, and process improvements [3] Expenses and Income - Selling, general and administrative (SG&A) expenses remained flat at $1.1 million, with increases in ESOP contributions and salaries offset by lower stock option expenses [4] - Other income rose to $0.4 million from $0.3 million, reflecting higher interest earned on cash and investment balances [4] Backlog and Orders - Total backlog increased to $134.7 million as of Dec. 31, 2025, from $120.1 million a year earlier, with $88.8 million tied to three significant customers [5] - New orders in the first half of fiscal 2026 totaled approximately $16.3 million, a decrease from $46.9 million in the prior-year period, with expectations for lower new orders compared to fiscal 2025 [6] Management Outlook - Management anticipates higher revenues in fiscal 2026 compared to fiscal 2025, driven by existing backlog, despite lighter first-half sales [7] - Full-year net income is expected to approximate fiscal 2025 levels [7] Risks and Challenges - The company cited ongoing inflationary pressures, tariffs, and potential supply chain or labor constraints as risks, but does not expect a material impact on fiscal 2026 operating income based on current conditions [8] Liquidity and Capital Position - Working capital was approximately $48.9 million at Dec. 31, 2025, up from $40.2 million a year earlier, with cash and cash equivalents totaling $17.8 million [9] - Operating cash flow for the six months was $2.9 million, down from $6.8 million in the prior-year period, primarily due to inventory builds and working capital changes [9] Other Developments - During the six months ended Dec. 31, 2025, Espey received $2 million in milestone reimbursements under a $3.4 million U.S. Navy funding award for facility and capital equipment upgrades, with completion expected by the end of fiscal 2026 [11]

Quick Read Coca-Cola (KO) gained 12.5% year-to-date versus flat S&P 500 returns. The biggest event this week was the company announcing earnings on February 10th. UBS raised Coca-Cola’s price target to $87 following 5% organic revenue growth in Q4. New CEO Braun said Coca-Cola innovation is not meeting standards and takes over March 31. A recent study identified one single habit that doubled Americans’ retirement savings and moved retirement from dream, to reality. Read more here. Coca-Cola (NYS ...